Assets under administration (‘‘AUA’’) include assets for which we provide administrative services such as client assets invested in other companies’ products that we offer outside of our wrap accounts.
These assets include those held in clients’ brokerage accounts.
We generally record fees received from administered assets as distribution fees.
We do not exercise management discretion over these assets and do not earn a management fee.
These assets are not reported on our Consolidated Balance Sheets.
AUA also includes certain assets on our Consolidated Balance Sheets for which we do not provide investment management services and do not recognize management fees, such as investments in non-affiliated funds held in the separate accounts of our life insurance subsidiaries.
These assets do not include assets under advisement, for which we provide model portfolios but do not have full discretionary investment authority.
The following table presents detail regarding our AUM and AUA:
## Table 0 ##
Total AUM increased $49.7 billion, or 8%, to $681.0 billion as of December 31, 2012 compared to the prior year due to a $20.3 billion increase in Asset Management AUM and a $19.9 billion increase in Advice & Wealth Management AUM.
See our segment results of operations discussion below for additional information on changes in our AUM.
Consolidated Results of Operations Year Ended December 31, 2012 Compared to Year Ended December 31, 2011 The following table presents our consolidated results of operations:
## Table 1 ##
The following table presents the total pretax impacts on our revenues and expenses attributable to unlocking and model changes for the years ended December 31:
## Table 2 ##
(1) Includes a $17 million benefit and a $14 million expense related to the market impact on variable annuity guaranteed benefits for the years ended December 31, 2013 and 2012, respectively.
The impact of unlocking and model changes for the year ended December 31, 2012 included a $41 million benefit, net of DAC and DSIC amortization, from an adjustment to the model which values the reserves related to living benefit guarantees primarily attributable to prior periods.
Net Revenues Net revenues increased $982 million, or 10%, to $11.2 billion for the year ended December 31, 2013 compared to $10.2 billion for the prior year primarily due to higher management and financial advice fees, distribution fees and other revenues.
Management and financial advice fees increased $561 million, or 12%, to $5.3 billion for the year ended December 31, 2013 compared to $4.7 billion for the prior year primarily due to higher asset-based fees driven by an increase in average AUM, as well as a shift to higher fee retail assets at Threadneedle and revenue enhancements related to various pricing adjustments.
Average AUM increased $41.0 billion, or 7%, compared to the prior year primarily due to market appreciation and wrap account net inflows, partially offset by asset management net outflows.
See our discussion on the changes in AUM in our segment results of operations section below.
Distribution fees increased $155 million, or 10%, to $1.8 billion for the year ended December 31, 2013 compared to $1.6 billion for the prior year due to higher client assets and increased client activity.
Net investment income decreased $44 million, or 2%, to $1.9 billion for the year ended December 31, 2013 compared to $1.9 billion for the prior year reflecting a $193 million decrease in investment income on fixed maturity securities, partially offset by a $30 million gain on the sale of Threadneedle’s investment in Cofunds in the second quarter of 2013 and a $110 million increase in net investment income of CIEs.
The decrease in investment income on fixed maturity securities was primarily due to low interest rates and approximately $126 million of lower investment income due to the sale of Ameriprise Bank’s investment portfolio as a result of the transition of banking operations.
Other revenues increased $240 million, or 30%, to $1.0 billion for the year ended December 31, 2013 compared to $795 million for the prior year due to the impact of unlocking, higher fees from variable annuity guarantees, and a $189 million increase in other revenues of CIEs.
Other revenues for the year ended December 31, 2013 included an $18 million negative impact from unlocking compared to a $41 million negative impact in the prior year.
The primary driver of the unlocking impact to other revenues in both years was lower projected gains on reinsurance contracts resulting from favorable mortality experience.
Other revenues for the prior year included $17 million of revenue from former banking operations.
Expenses Total expenses increased $250 million, or 3%, to $9.2 billion for the year ended December 31, 2013 compared to $9.0 billion for the prior year primarily due to increases in distribution expenses and benefits, claims, losses and settlement expenses, partially offset by decreases in amortization of DAC and general and administrative expense.
Distribution expenses increased $338 million, or 13%, to $3.0 billion for the year ended December 31, 2013 compared to $2.7 billion for the prior year driven by growth in assets under management.
See our discussion on the changes in AUM in our segment results of operations section below.
Interest credited to fixed accounts decreased $25 million, or 3%, to $806 million for the year ended December 31, 2013 compared to $831 million for the prior year driven by lower average fixed annuity account balances.
Average fixed annuities contract accumulation values decreased $508 million, or 4%, to $13.5 billion for the year ended December 31, 2013 compared to the prior year due to net outflows.
Fixed annuities remain in net outflows due to low client demand given the interest rate environment.
Ameriprise Advisor Group Deferred Compensation Plan The Advisor Group Deferral Plan, which was created in April 2009, allows for employee advisors to receive share-based bonus awards which are subject to future service requirements and forfeitures.
The Advisor Group Deferral Plan is an unfunded non-qualified deferred compensation plan under section 409A of the Internal Revenue Code.
The Advisor Group Deferral Plan also gives qualifying employee advisors the choice to defer a portion of their base salary or commissions.
This deferral can be in the form of Ameriprise Financial stock or other investment options.
Deferrals are not subject to future service requirements or forfeitures.
Under the Advisor Group Deferral Plan, a maximum of 3.0 million shares may be issued.
Awards granted under the Advisor Group Deferral Plan may be settled in cash and/or shares of the Company’s common stock according to the award’s terms.
Share units receive dividend equivalents, as dividends are declared by the Company’s Board of Directors, until distribution and are subject to forfeiture until vested.
Full Value Share Award Activity A summary of activity for the Company’s restricted stock awards, restricted stock units granted to employees (including advisors), compensation deferrals into stock and deferred share units for 2016 is presented below (shares in millions):
## Table 3 ##
The deferred shares in the table above primarily relate to franchise advisor voluntary deferrals of their commissions into Ameriprise Financial stock under the Franchise Advisor Deferral Plan that are fully vested at the deferral date.
The fair value of full value share awards vested during the years ended December 31, 2016, 2015 and 2014 was $103 million, $133 million and $259 million, respectively.
The weighted average grant date fair value for restricted shares, restricted stock units and deferred share units during 2016, 2015 and 2014 was $88.61, $128.43 and $109.60, respectively.
The weighted average grant date fair value for franchise advisor and advisor group deferrals during 2016, 2015 and 2014 was $94.55, $123.88 and $114.69, respectively.
Performance Share Units Under the 2005 ICP, the Company’s Executive Leadership Team may be awarded a target number of performance share units (‘‘PSUs’’).
PSUs will be earned only to the extent that the Company attains certain goals relating to the Company’s performance and relative total shareholder returns against peers over a three-year period.
The awards also have a three-year service condition with cliff vesting with an accelerated service condition based on age and length of service.
The actual number of PSUs ultimately earned could vary from zero, if performance goals are not met, to as much as 200% of the target, if performance goals are significantly exceeded.
The value of each target PSU is equal to the value of one share of Ameriprise common stock.
The total amount of target PSUs outstanding at the end of December 31, 2016, 2015 and 2014 was 0.2 million.
The PSUs are liability awards.
During the years ended December 31, 2016, 2015 and 2014, the value of shares settled for PSU awards was $15 million, $27 million and $20 million, respectively.
Threadneedle Equity Incentive Plan (‘‘EIP’’) Prior to 2012, certain key Threadneedle employees were eligible for awards under the EIP based on a formula tied to Threadneedle’s financial performance.
Awards under the EIP were first made in April 2009; prior awards were made under the equity participation plan (‘‘EPP’’).
The EPP and EIP awards were fully amortized as of December 31, 2015.
During the years ended December 31, 2016, 2015 and 2014, cash settlements of EPP and EIP awards were $2 million, $28 million and $28 million, respectively.
United States, fail to either complete treatment or show a long-term sustained response to therapy.
As a result, we believe new safe and effective treatment options for HCV infection are needed.
Telaprevir Development Program We are conducting three major Phase 2b clinical trials of telaprevir.
PROVE 1 is ongoing in the United States and PROVE 2 is ongoing in European Union, both in treatment-na?ve patients.
PROVE 3 has commenced and is being conducted with patients in North America and the European Union who did not achieve sustained viral response with previous interferon-based treatments.
PROVE 1 and PROVE 2 are fully enrolled, and we commenced patient enrollment in PROVE 3 in January 2007.
PROVE 1 and PROVE 2 We expect that together, the PROVE 1 and PROVE 2 clinical trials will evaluate rates of sustained viral response, or SVR, in approximately 580 treatment-na?ve patients infected with genotype 1 HCV, including patients who will receive telaprevir and patients in the control arms.
SVR is defined as undetectable viral levels 24 weeks after all treatment has ceased.
A description of each of the clinical trial arms for the PROVE 1 and PROVE 2 clinical trials, including the intended number of patients in each trial, is set forth in the following table:

Tables referenced above, in order (Table 0 first):
<table><tr><td> </td><td colspan="2">December 31,</td><td></td><td></td></tr><tr><td> </td><td>2012</td><td>2011</td><td colspan="2">Change</td></tr><tr><td> </td><td colspan="3">(in billions)</td><td></td></tr><tr><td> Assets Under Management and Administration</td><td></td><td></td><td></td><td></td></tr><tr><td>Advice & Wealth Management AUM</td><td>$125.0</td><td>$104.7</td><td>$20.3</td><td>19%</td></tr><tr><td>Asset Management AUM</td><td>455.4</td><td>435.5</td><td>19.9</td><td>5</td></tr><tr><td>Eliminations</td><td>-18.0</td><td>-12.6</td><td>-5.4</td><td>-43</td></tr><tr><td> Total Assets Under Management</td><td>562.4</td><td>527.6</td><td>34.8</td><td>7</td></tr><tr><td> Total Assets Under Administration</td><td>118.6</td><td>103.7</td><td>14.9</td><td>14</td></tr><tr><td> Total AUM and AUA</td><td>$681.0</td><td>$631.3</td><td>49.7</td><td>8%</td></tr></table>
<table><tr><td> </td><td colspan="2">Years Ended December 31,</td><td></td><td></td></tr><tr><td> </td><td>2012</td><td>2011</td><td colspan="2">Change</td></tr><tr><td> </td><td colspan="3">(in millions)</td><td></td></tr><tr><td> Revenues</td><td></td><td></td><td></td><td></td></tr><tr><td>Management and financial advice fees</td><td>$4,692</td><td>$4,537</td><td>$155</td><td>3%</td></tr><tr><td>Distribution fees</td><td>1,616</td><td>1,573</td><td>43</td><td>3</td></tr><tr><td>Net investment income</td><td>1,933</td><td>2,046</td><td>-113</td><td>-6</td></tr><tr><td>Premiums</td><td>1,223</td><td>1,220</td><td>3</td><td>—</td></tr><tr><td>Other revenues</td><td>795</td><td>863</td><td>-68</td><td>-8</td></tr><tr><td>Total revenues</td><td>10,259</td><td>10,239</td><td>20</td><td>—</td></tr><tr><td>Banking and deposit interest expense</td><td>42</td><td>47</td><td>-5</td><td>-11</td></tr><tr><td>Total net revenues</td><td>10,217</td><td>10,192</td><td>25</td><td>—</td></tr><tr><td> Expenses</td><td></td><td></td><td></td><td></td></tr><tr><td>Distribution expenses</td><td>2,698</td><td>2,559</td><td>139</td><td>5</td></tr><tr><td>Interest credited to fixed accounts</td><td>831</td><td>856</td><td>-25</td><td>-3</td></tr><tr><td>Benefits, claims, losses and settlement expenses</td><td>1,846</td><td>1,557</td><td>289</td><td>19</td></tr><tr><td>Amortization of deferred acquisition costs</td><td>286</td><td>397</td><td>-111</td><td>-28</td></tr><tr><td>Interest and debt expense</td><td>276</td><td>317</td><td>-41</td><td>-13</td></tr><tr><td>General and administrative expense</td><td>3,042</td><td>3,059</td><td>-17</td><td>-1</td></tr><tr><td>Total expenses</td><td>8,979</td><td>8,745</td><td>234</td><td>3</td></tr><tr><td>Income from continuing operations before income tax provision</td><td>1,238</td><td>1,447</td><td>-209</td><td>-14</td></tr><tr><td>Income tax provision</td><td>335</td><td>377</td><td>-42</td><td>-11</td></tr><tr><td>Income from continuing operations</td><td>903</td><td>1,070</td><td>-167</td><td>-16</td></tr><tr><td>Loss from discontinued operations, net of tax</td><td>-2</td><td>-60</td><td>58</td><td>97</td></tr><tr><td>Net income</td><td>901</td><td>1,010</td><td>-109</td><td>-11</td></tr><tr><td>Less: Net loss attributable to noncontrolling interests</td><td>-128</td><td>-106</td><td>-22</td><td>-21</td></tr><tr><td>Net income attributable to Ameriprise Financial</td><td>$1,029</td><td>$1,116</td><td>$-87</td><td>-8%</td></tr></table>
<table><tr><td>Pretax Increase (Decrease)</td><td>2013</td><td>2012</td></tr><tr><td></td><td colspan="2">(in millions)</td></tr><tr><td>Other revenues</td><td>$-18</td><td>$-41</td></tr><tr><td>Benefits, claims, losses and settlement expenses</td><td>-5</td><td>-28</td></tr><tr><td>Amortization of DAC</td><td>-79</td><td>23</td></tr><tr><td>Interest credited to fixed accounts</td><td>—</td><td>2</td></tr><tr><td>Total expenses</td><td>-84</td><td>-3</td></tr><tr><td>Total<sup>-1</sup></td><td>$66</td><td>$-38</td></tr></table>
<table><tr><td></td><td>Shares</td><td>Weighted Average Grant-date Fair Value</td></tr><tr><td>Non-vested shares at January 1</td><td>1.3</td><td>$103.01</td></tr><tr><td>Granted</td><td>0.9</td><td>89.07</td></tr><tr><td>Deferred</td><td>0.3</td><td>96.22</td></tr><tr><td>Vested</td><td>-1.1</td><td>94.15</td></tr><tr><td>Forfeited</td><td>-0.1</td><td>101.96</td></tr><tr><td>Non-vested shares at December 31</td><td>1.3</td><td>99.37</td></tr></table>

Question: What's the average of the Distribution fees in table 1 in the years where Distribution fees in table 1 is positive? (in millions)
Answer: 1594.5
Reasoning program: add(1616,1573), divide(#0,const_2)